There were 230 press releases posted in the last 24 hours and 170,807 in the last 365 days.

Natus Medical Announces Third Quarter 2016 Financial Results

  • Reports third quarter revenue of $90.9 million
  • Reports third quarter GAAP earnings per share of $0.40 and non-GAAP of $0.39
  • Reports GAAP gross margin of 63.9% and non-GAAP gross margin of 64.6%
  • Achieves cash flow from operations of $35.5 million, adjusted cash flow of $22.4 million

PLEASANTON, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:BABY) today announced financial results for the three months ended September 30, 2016.

For the third quarter ended September 30, 2016, the Company reported revenue of $90.9 million, a decrease of 3.9% compared to $94.6 million reported for the third quarter 2015. GAAP Gross profit margin was 63.9% vs. 61.7% reported for the third quarter 2015. GAAP net income was $13.2 million, or $0.40 per diluted share, compared with GAAP net income of $10.9 million, or $0.33 per diluted share in the third quarter 2015, representing a 21% increase in GAAP earnings per diluted share.

Non-GAAP earnings per diluted share was $0.39 for the third quarter 2016, compared to $0.39 in the third quarter 2015. Non-GAAP net income was $12.8 million for the third quarter ended September 30, 2016 compared to the prior year's non-GAAP net income of $12.9 million. Non-GAAP Gross profit margin was 64.6% vs. 62.5% reported for the third quarter of 2015. 

For the nine months ended September 30, 2016, the Company reported revenue of $274.2 million, a decrease of 0.6% compared to $275.9 million reported for the same period in 2015. GAAP Gross profit margin was 61.9% vs. 61.4% reported for the same period in 2015. GAAP net income was $32.2 million, or $0.97 per diluted share, compared with GAAP net income of $29.4 million, or $0.89 per diluted share in the same period in 2015, staying constant in GAAP earnings per diluted share.

Non-GAAP earnings per diluted share increased 7% to $1.11 for the first nine months in 2016, compared to $1.04 in the same period in 2015. The Company reported non-GAAP net income of $36.7 million for the nine months ended September 30, 2016, compared to the prior year's non-GAAP net income of $34.4 million.

Combined cash and investments increased by $10.2 million to $106.5 million during the quarter. The Company repurchased $1.5 million of its stock during the third quarter of 2016. Cash flow from operations for the third quarter was $35.5 million and includes $13.1 million of net cash increase from Venezuela prepayments, resulting in an adjusted cash flow from operations of $22.4 million. 

"I am pleased with our non-GAAP earnings of $0.39 and our non-GAAP gross margin of 64.6% considering our reduced revenue.  As previously reported, our revenue shortfall was the result of certain voluntary product ship holds and softness in our international markets," said Jim Hawkins, President and Chief Executive Officer of the Company.

"We now expect our recently announced acquisition of Otometrics to close on January 1, 2017.  With Otometrics next year, we look forward to achieving $500 million in revenue, an important milestone for Natus.  We expect Otometrics to be accretive to our 2017 earnings with a non-GAAP contribution operating margin goal for the year of 10% and a 2018 goal of 20%," said Hawkins.

Financial Guidance

The Company provided revenue and earnings guidance for the fourth quarter and updated its revenue and earnings guidance for the full year 2016.

For the fourth quarter 2016, the Company expects revenue of $107.0 million to $109.0 million, GAAP earnings per share of $0.46 to $0.49 and non-GAAP earnings per share guidance of $0.52 to $0.55.

The Company adjusted its full year 2016 revenue guidance and now expects revenue of $381.2 million to $383.2 million. Full year 2016 guidance for GAAP earnings per share is $1.43 to $1.46.  Non-GAAP earnings per share guidance is being updated to $1.63 to $1.66.

Fourth quarter and full year revenue and earnings guidance includes approximately $7 million in shipments and service under its supply agreement with Venezuela.

The Company's non-GAAP earnings guidance excludes amortization of acquisition related intangibles, acquisition related charges, restructuring charges, and their related tax effects. All non-GAAP earnings per share amounts are on a diluted basis.

Use of Non-GAAP Financial Measures

The Company presents in this release its non-GAAP net income, non-GAAP earnings per share, non-GAAP gross margin and non-GAAP operating margin results which exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, certain discreet items, direct costs of acquisitions and the related tax effects. A reconciliation between non-GAAP and GAAP financial measures is included in this press release.

The Company believes that the presentation of results excluding these charges or gains provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results and better reflects the ongoing economics of the Company's operations. The Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.

Specifically, the Company excludes the following charges, gains, and their related tax effects in the calculation of non-GAAP net income, non-GAAP earnings per share and non-GAAP operating expense and excludes all but Restructuring charges from the calculation of non-GAAP gross margin: 1) Non-cash amortization expense associated with certain acquisition-related intangibles. The charges reflect an estimate of the cost of acquired intangible assets over their estimated useful lives. 2) Restructuring charges. The Company has over time completed multiple acquisitions of other companies and businesses. Following an acquisition the Company will, as it determines appropriate, initiate restructuring events to eliminate redundant costs. Restructuring expenses which are excluded in the non-GAAP items are exclusively related to permanent reductions in our workforce and redundant facility closures. 3) Certain discreet items. These items represent significant infrequent charges or gains that management believes  should be viewed outside of normal operating results. These items are specifically identified when they occur. 4) Direct costs of acquisitions.  These are direct acquisition-related costs that occur when the Company makes an acquisition, such as professional fees, due diligence costs, and earn-out adjustments.

The Company applies GAAP methodologies in computing its non-GAAP tax provision by determining the annual expected effective tax rate after taking into account items excluded for non-GAAP financial reporting purposes.  The Company’s non-GAAP tax expense and its non-GAAP effective tax rate are generally higher than its GAAP tax expense and GAAP effective tax rate because the income subject to taxes would be higher due to the effect of the items excluded from non-GAAP financial reporting. 

The Company's management uses these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods and the Company believes that investors also benefit from being able to refer to these non-GAAP financial measures along with the GAAP operating results. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.

Conference Call

Natus has scheduled an investment-community conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) today, October 19, 2016. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 94693349. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 94693349. The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company’s Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments in neurological dysfunction, epilepsy, sleep disorders, newborn care, hearing impairment and balance and mobility disorders.

Additional information about Natus Medical can be found at www.natus.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding our long term goals of revenue growth, improved margins, revenue and GAAP and non‑GAAP profitability for the fourth quarter and full year 2016. These statements relate to estimates and assumptions regarding future events including Natus' future financial performance. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, the demand for our products and services, the impact of adverse global economic conditions on our target markets, negative effects of currency exchange rates, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, risks associated with bringing new products to market and integrating acquired businesses, including RetCam, risks associated with our Venezuela contract, risks associated with product recalls and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2015 and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.              

 
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(in thousands, except per share amounts)
               
   Quarter Ended    Year to Date
  September 30,
2016
  September 30,
2015
  September 30,
2016
  September 30,
2015
Revenue $ 90,906     $ 94,583     $ 274,193     $ 275,915  
Cost of revenue 32,194     35,520     102,542     104,468  
Intangibles amortization 612     683     1,818     2,048  
Gross profit 58,100     58,380     169,833     169,399  
Gross profit margin 63.9 %   61.7 %   61.9 %   61.4 %
Operating expenses:              
Marketing and selling 19,746     22,495     61,578     65,345  
Research and development 7,689     7,700     22,596     21,867  
General and administrative 12,822     10,031     37,225     33,239  
Intangibles amortization 2,409     2,036     6,741     5,165  
Restructuring 197     42     1,315     358  
Total operating expenses 42,863     42,304     129,455     125,974  
Income from operations 15,237     16,076     40,378     43,425  
Other income/(expense), net (893 )   7     (412 )   (1,203 )
Income before tax 14,344     16,083     39,966     42,222  
Provision for income tax expense 1,182     5,151     7,754     12,842  
Net income $ 13,162     $ 10,932     $ 32,212     $ 29,380  
Earnings per share:              
Basic $ 0.41     $ 0.34     $ 0.99     $ 0.91  
Diluted $ 0.40     $ 0.33     $ 0.97     $ 0.89  
Weighted-average shares:              
Basic 32,388     32,432     32,476     32,279  
Diluted 32,981     33,253     33,077     33,194  

/EIN News/ --

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands)
           
  September 30,   June 30,   December 31,
  2016   2016   2015
ASSETS          
           
Current assets:          
Cash and investments $ 106,521     $ 96,284     $ 82,469  
Accounts receivable, net 84,870     93,102     99,080  
Inventories 51,654     43,620     48,572  
Other current assets 22,789     12,925     11,235  
Total current assets 265,834     245,931     241,356  
           
Property and equipment, net 18,127     17,174     16,967  
Goodwill and intangible assets 194,693     192,173     194,002  
Deferred income tax 12,694     12,809     12,782  
Other assets 19,236     18,005     14,389  
Total assets $ 510,584     $ 486,092     $ 479,496  
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable $ 17,107     $ 18,836     $ 23,660  
Short-term borrowings     10,000      
Accrued liabilities 38,711     37,306     42,137  
Deferred revenue 33,334     11,262     11,311  
Total current liabilities 89,152     77,404     77,108  
           
Deferred income tax 3,819     3,839     3,897  
Other long-term liabilities 8,358     8,632     7,781  
Total liabilities 101,329     89,875     88,786  
Total stockholders’ equity 409,255     396,217     390,710  
Total liabilities and stockholders’ equity $ 510,584     $ 486,092     $ 479,496  


NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)
(in thousands)
   
   Quarter Ended
  September 30,
2016
  September 30,
2015
Operating activities:      
Net income $ 13,162     $ 10,933  
Adjustments to reconcile net income to net cash provided by operating activities:      
Provision for losses on accounts receivable 180     362  
Excess tax benefit on the exercise of stock options     (933 )
Depreciation and amortization 4,424     4,168  
Loss on disposal of property and equipment 11      
Warranty reserve 960     1,618  
Share-based compensation 1,954     1,891  
Changes in operating assets and liabilities:      
Accounts receivable 11,705     (5,714 )
Inventories (6,704 )   (2,134 )
Prepaid expenses and other assets (11,320 )   (3,332 )
Accounts payable (1,376 )   5,103  
Accrued liabilities (2,464 )   3,406  
Deferred revenue 24,871     (830 )
Deferred income tax 106     867  
Net cash provided by operating activities 35,509     15,405  
Investing activities:      
Acquisition of businesses, net of cash acquired (9,699 )    
Purchases of property and equipment (74 )   (615 )
Purchase of intangible assets 32     (268 )
Purchase of short-term investments (34,921 )    
Net cash used in investing activities (44,662 )   (883 )
Financing activities:      
Proceeds from stock option exercises and Employee Stock Purchase Program purchases 343     371  
Excess tax benefit on the exercise of stock options     933  
Repurchase of common stock (1,503 )   (3,837 )
Taxes paid related to net share settlement of equity awards (1,362 )   (2,654 )
Deferred debt issuance costs (533 )    
Payments on borrowings (10,000 )    
Net cash used in financing activities (13,055 )   (5,187 )
Exchange rate changes effect on cash and cash equivalents (2,476 )   (372 )
Net increase in cash and cash equivalents (24,684 )   8,963  
Cash and cash equivalents, beginning of period 96,284     82,469  
Cash and cash equivalents, end of period $ 71,600     $ 91,432  


NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (UNAUDITED)
(in thousands, except per share amounts)
       
  Quarter Ended
  September 30,
2016
  September 30,
2015
GAAP based results:      
Income before provision for income tax $ 14,344     $ 16,083  
       
Non-GAAP adjustments:      
Intangibles Amortization - Cost of revenue 612     683  
Intangibles Amortization - Operating expense 2,409     2,036  
Restructuring 1 197     42  
Direct costs of acquisitions (M&S) 2 (2,827 )    
Direct costs of acquisitions (G&A) 379      
Direct costs of acquisitions (OI&E) 37      
Non-GAAP income before provision for income tax 15,151     18,844  
       
Income tax expense, as adjusted 2,370     5,900  
       
Non-GAAP net income $ 12,781     $ 12,944  
Non-GAAP earnings per share:      
Basic $ 0.39     $ 0.40  
Diluted $ 0.39     $ 0.39  
       
Weighted-average shares used to compute      
Basic non-GAAP earnings per share 32,388     32,432  
Diluted non-GAAP earnings per share 32,981     33,253  
       
GAAP Gross profit 58,100     58,380  
Amortization of intangibles 612     683  
Non-GAAP Gross Profit 58,712     59,063  
Non-GAAP Gross Margin 64.6 %   62.5 %
       
GAAP Operating profit 15,237     16,076  
Amortization of intangibles 3,021     2,719  
Restructuring and other charges (2,251 )   42  
Non-GAAP Operating profit 16,007     18,837  
Non-GAAP Operating margin 17.6 %   19.9 %

1 Restructuring costs primarily consist of facility abandonment charges related to our Munich, Germany and Austin, Texas facilities, and severance costs associated with the ceasing operations in Munich, Germany.
2 Amount represents a reduction in our anticipated earn-out payment for the GND acquisition.

 
NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (UNAUDITED)
(in thousands, except per share amounts)   
       
   Quarter Ended
  September 30,
2016
  September 30,
2015
GAAP Provision for income tax expense 1,182     5,151  
Effect of accumulated change of pretax income 621     869  
Effect of change in annual expected tax rate 567     (123 )
Non-GAAP Income tax expense, as adjusted 2,370     5,897  
       
   Quarter Ended    Year to Date
  December 31,
2016
  December 31,
2016
GAAP EPS Guidance $0.46 - $0.49   $1.43 - $1.46
Amortization of Intangibles   0.08       0.34  
Restructuring     0.04  
Recall Accrual     0.01  
Direct cost of acquisitions     (0.09 )
Tax effect   (0.02 )     (0.1 )
Non-GAAP EPS Guidance $0.52 - $0.55   $1.63 - $1.66

 

Natus Medical Incorporated
Jonathan A. Kennedy
Executive Vice President and Chief Financial Officer
(925) 223-6700
InvestorRelations@Natus.com 

Primary Logo